Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Oncosil Medical Ltd

OSL.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Micro Cap Analyst: N/A

Last Close

$0.90

▲ +0.79%

Market Cap $27.67M · Vol 75.32K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$27.67M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

55.32

Momentum

Beta

2.73

vs Market

52W High

$1.47

34.34% below

52W Low

$0.26

241.89% above

Volume

75.32K

Avg 230.73K

P/B

5.50

Price-to-book

ROE

N/A

Return on equity

Free Float

90.13%

Public shares

Shariah Compliance8 STANDARDS

✗ Oncosil Medical Ltd (OSL.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OSL.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.01%

-7.64%

+182.22%

+86.76%

YTD

+31.68%

+14.04%

-66.28%

-91.90%

Financials & Valuation

TTM · Annual

Total Revenue	$830.19K
Net Income	$-9,935,674.00
Revenue Growth (YoY)	+66.13%
Gross Margin	-78.62%
Operating Margin	-1,217.59%
Net Profit Margin	-1,196.80%
ROE	N/A
ROA · ROIC	-217.79% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	10.39
P/B	5.50
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	30.89M

Technical Indicators

50-Day SMA	$0.71
200-Day SMA	$0.58
RSI (14)	55.32
Beta	2.73
52-Week High	$1.47
52-Week Low	$0.26

Volume Today	75.32K
Avg Daily Volume (30D)	230.73K
Relative Volume	0.33x
Volatility (10D)	106.64
Volatility (30D)	121.28
Free Float	90.13%

Analyst Consensus

N/A

Current Price $0.90

Mean Target $1.01

52W Low$0.26 52W High$1.47

Current

Target

$0.26 $1.47

Current Analyst target

+12.25% upside potential · 1 analysts

Identifiers

ExchangeASX

FIGIBBG001SP2KV0

ISINAU000000OSL3

CountryAustralia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateAug 27, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.